Jeffrey S. Wefel, PhD, ABPP

Peer-Reviewed Articles

1. Freedland SJ, Aronson W, Asher A, Golant M, Lemke E, Morgans AK, Morris D, Sullivan C, Sutton J, Thomson CA, Twardowski P, Wefel JS, Winters-Stone K, Chakoian M, Wells T, ElSouda D, Turnbull J, Buzaglo J, Mobley C, Ivanova J, Cohen J, Hogue S, El-Chaar N, Touya M. Consensus recommendations for disease- and treatment-related fatigue in patients with advanced prostate cancer: A modified Delphi panel. e-Pub 2025.
2. Yeboa DN, Whitfield BT, Lin R, Ejezie CL, Swanson TA, Beckham TH, Wang C, De B, Perni S, Tom MC, Li J, McGovern SL, Harrison R, Majd NK, Puduvalli VK, Aaroe AE, Loghin M, O'Brien BJ, Patel AD, Patel CB, Wefel JS, Taslicay CA, Gule-Monroe M, Paulino AC, McAleer MF, Grosshans DR, Ghia AJ, Jiang W, Chung C, Maor M, Yang CH, Gubbiotti MA, Kamiya-Matsuoka C, Ballester LY, Weathers SP, Huse JT. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy. J Neurooncol 176(1):72, 2025. e-Pub 2025. PMID: 41191157.
3. Omuro A, DeAngelis LM, Polley MC, Correa D, Wefel JS, Bovi JA, Rosenblum M, Corn BW, Aneja S, Grommes C, Peereboom DM, Lallana EC, Werner-Wasik M, Rogers CL, Iwamoto FM, Yu HM, Donnelly ED, Struve TD, Won M, Mehta MP. Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma. Neuro Oncol, 2025. e-Pub 2025. PMID: 41189315.
4. Wefel JS, Schagen SB. Neuropsychological sequelae of cancer and cancer therapy. J Clin Exp Neuropsychol 47(8):701-706, 2025. e-Pub 2025. PMID: 41378822.
5. Bander ED, Noll KR, Andrade de Almeida RA, Seaman SC, Banu M, Clark VE, Suki D, Wefel JS, Bradshaw M, Ferguson S, Weinberg JS, Lang FF, Prabhu SS. Relationships Between Surgical Approach, Tumor Classification Scheme, and Early Neurocognitive Outcome After Awake Craniotomy for Resection of Insular Glioma. Oper Neurosurg, 2025. e-Pub 2025. PMID: 40985652.
6. Noll KR, Wefel JS. Characterization, etiology, and management of neurocognitive impairment in patients with glioma: an evidentiary update. Curr Opin Neurol, 2025. PMID: 40948080.
7. McLeod A, Gabel K, Chakos K, Wefel JS, Tussing-Humphreys L, Oddo VM. The effect of Mediterranean Diet adherence on the relationship between cognitive performance and cancer survivorship. J Cancer Surviv, 2025. e-Pub 2025. PMID: 40789996.
8. Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol:JCO2500618, 2025. e-Pub 2025. PMID: 40779733.
9. Corn BW, Paulus R, Gondi V, Mehta MP, Fogh S, Wefel JS, Videtic GM, Sun A, Yoon H, Heinzerling JH, McGarry RC, Kundapur V, Devisetty K, Wu A, McCarron EC, Pollock J, Kanner AA, Feldman DB, Pugh SL, Kachnic LA, Movsas B. "Hope" Drives Quality of Life in Patients With Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003. Int J Radiat Oncol Biol Phys, 2025. e-Pub 2025. PMID: 40614783.
10. Yeboa DN, Li J, Lin R, Prabhu SS, Beckham TH, Woodhouse K, Swanson TA, Weinberg JS, Wang X, Chi X, Ejezie CL, Suki D, Wang C, Ene C, McCutcheon IE, McGovern S, McAleer MF, Tom M, Ghia A, Perni S, Jiang W, De B, Chung C, Kim BYS, O'Brien BJ, Huse JT, Wefel JS, Court L, Tawbi H, Janku F, Guha-Thakurta N, Debnam JM, Johnson J, Taslicay CA, Alvarez-Breckenridge C, Raza SM, Heimberger AB, DeMonte F, North R, Briere TM, de Groot JF, Sawaya R, Grosshans D, Lang FF, Rao G, Ferguson SD. Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial. JAMA Oncol, 2025. e-Pub 2025. PMID: 40531511.
11. Danielsen, JT, Zachariae, R, Schmidt, H, Kallehauge, JF, Thomadsen, JK, Wefel, JS, Wu, LM, Amidi, A. Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors. Cancer 131(2), 2025. e-Pub 2025. PMID: 39663713.
12. Noll KR, Bander ED, Chen HS, Bradshaw M, Wefel JS, Kumar VA, Prabhu SS, Liu HL. Changes in functional connectivity are associated with functional independence in the early postoperative period following awake surgical resection of language-eloquent glioma. Neurooncol Adv 7(1):vdaf192, 2025. e-Pub 2025. PMID: 41019665.
13. Wefel JS, Schagen, S. B.. Neuropsychological sequelae of cancer and cancer therapy. Journal of Clinical and Experimental Neuropsychology 47(8):701-706, 2025. e-Pub 2025.
14. Noll KR, Bander ED, Chen HS, Bradshaw M, Wefel JS, Kumar VA, Prabhu SS, Liu H. Changes in functional connectivity are associated with functional independence in the early postoperative period following awake surgical resection of language-eloquent glioma. Neuro-Oncology Advances, 2025. e-Pub 2025.
15. Beer TM, George DJ, Shore ND, Winters-Stone K, Wefel JS, Verholen F, Srinivasan S, Ortiz J, Morgans AK. Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. Oncologist 25:oyae287, 2024. PMID: 39450762.
16. Janelsins MC, Van Dyk K, Hartman SJ, Koll TT, Cramer CK, Lesser GJ, Barton DL, Mustian KM, Wagner LI, Ganz PA, Cole PD, Bakos A, Root JC, Hardy K, Magnuson A, Ferguson RJ, McDonald BC, Saykin AJ, Gonzalez BD, Wefel JS, Morilak DA, Dahiya S, Heijnen CJ, Conley YP, Morgans AK, Mabbott D, Monje M, Rapp SR, Gondi V, Bender C, Embry L, McCaskill Stevens W, Hopkins JO, St Germain D, Dorsey SG. The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment. J Natl Cancer Inst 9:djae209. e-Pub 2024. PMID: 39250738.
17. Katlowitz, KA, Beckham, TH, Kudchadker, RJ, Wefel, JS, Elamin, YY, Weinberg, J. A Novel Multimodal Approach to Refractory Brain Metastases. Advances in Radiation Oncology 9(2), 2024. e-Pub 2024. PMID: 38405307.
18. Noll KR, Asman P, Tasnim I, Hall M, Connelly K, Swamy C, Ene C, Tummala S, Grasu RM, Liu HL, Kumar VA, Muir M, Prinsloo S, Michener H, Wefel JS, Ince NF, Prabhu SS. Intraoperative language mapping guided by real-time visualization of gamma band modulation electrocorticograms: Case report and proof of concept. Neurooncol Pract 11(1):npad059, 2024. e-Pub 2024. PMID: 38222047.
19. Cowan BA, Olivier K, Tombal B, Wefel JS. Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes. Adv Ther 41(2):476-491, 2024. e-Pub 2024. PMID: 37979089.
20. Catalino MP, Noll KR, Wefel JS, Michener H, Prinsloo S, Tummala S, Prabhu S. Decoding the clinical effects of low-grade glioma-induced cortical excitability. J Neurosurg 140(1):18-26, 2024. e-Pub 2024. PMID: 37439490.
21. Wefel JS, Deshmukh S, Brown PD, Grosshans DR, Sulman EP, Cerhan JH, Mehta MP, Khuntia D, Shi W, Mishra MV, Suh JH, Laack NN, Chen Y, Curtis AA, Laba JM, Elsayed A, Thakrar A, Pugh SL, Bruner DW. Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614. Int J Radiat Oncol Biol Phys 13:S0360-3016(23):08238-X, 2023. e-Pub 2023. PMID: 38101486.
22. Yaniv, D, Niccolai, LM, Wefel, JS, Sullaway, C, Phan, J, Fuller, C, Haroun, KB, Hanna, EY, Su, SY. Neurocognitive Functioning of Patients with Sinonasal and Nasopharyngeal Cancers Treated with Multimodality Therapy. Journal of Neurological Surgery, Part B: Skull Base 85(6):614-621, 2023. e-Pub 2023. PMID: 39483162.
23. Noll KR, Asman P, Tasnim I, Hall M, Connelly K, Swamy C, Ene C, Tummala S, Grasu RM, Liu HL, Kumar VA, Muir M, Prinsloo S, Michener H, Wefel JS, Ince NF, Prabhu SS. Intraoperative language mapping guided by real-time visualization of gamma band modulation electrocorticograms: Case report and proof of concept. Neurooncol Pract 11(1):92-100, 2023. e-Pub 2023. PMID: 38222047.
24. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37402581.
25. Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, Usuki KY, Baschnagel AM, Mehta MP, Kachnic LA. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms with Hippocampal Avoidance during Whole-Brain Radiotherapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys S0360-3016(23):00438-8, 2023. e-Pub 2023. PMID: 37150264.
26. Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, Ansell PJ, Samanta S, Kundu MG, Armstrong TS, Wefel JS, Seidel C, de Vos FY, Hsu S, Cardona AF, Lombardi G, Bentsion D, Peterson RA, Gedye C, Bourg V, Wick A, Curran WJ, Mehta MP. Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol 25(2):339-350, 2023. e-Pub 2023. PMID: 35849035.
27. Holdhoff M, Nicholas MK, Peterson RA, Maraka S, Liu LC, Fischer JH, Wefel JS, Fan TM, Vannorsdall T, Russell M, Iacoboni M, Tarasow TM, Hergenrother PJ, Dudek AZ, Danciu OC. Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas. Neurooncol Adv 5(1):vdad087, 2023. e-Pub 2023. PMID: 37554223.
28. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv 5(1):vdad032, 2023. e-Pub 2023. PMID: 37114244.
29. Katlowitz, K A, Beckham, T H, Kudchadker, R J, Wefel, J, Elamin, Y Y, Weinberg, J S. A Novel Multimodal Approach to Refractory Brain Metastases: A Case Report. Advances in Radiation Oncology:101349, 2023. e-Pub 2023.
30. Noll, KR, Wefel, JS. On the classification of impairment in neuropsychological research and practice in the neuro-oncological setting. Neuro-Oncology Practice 9(4):255-256, 2022. e-Pub 2022. PMID: 35859538.
31. Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399(10338):1886-1901, 2022. e-Pub 2022. PMID: 35569466.
32. Chung C, Brown PD, Wefel JS. Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial. Neuro Oncol 24(5):851, 2022. e-Pub 2022. PMID: 35460425.
33. Muir M, Patel R, Traylor J, de Almeida Bastos DC, Prinsloo S, Liu HL, Noll K, Wefel J, Tummala S, Kumar V, Prabhu S. Validation of Non-invasive Language Mapping Modalities for Eloquent Tumor Resection: A Pilot Study. Front Neurosci 16:833073, 2022. e-Pub 2022. PMID: 35299624.
34. Chung C, Brown PD, Wefel JS. Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al. Neuro Oncol 23(11):1982, 2021. e-Pub 2021. PMID: 34453547.
35. Parsons MW, Peters KB, Floyd SR, Brown P, Wefel JS. Preservation of neurocognitive function in the treatment of brain metastases. Neurooncol Adv 3(5):v96-v107, 2021. e-Pub 2021. PMID: 34859237.
36. Wefel JS, Zhou R, Sulman EP, Boehling NS, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Kahalley LS, Small BJ, Scheurer ME, Bondy ML, Liu Y. Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. J Neurooncol 156(1):185-193, 2021. e-Pub 2021. PMID: 34817796.
37. De Witt Hamer PC, Klein M, Hervey-Jumper SL, Wefel JS, Berger MS. In Reply: Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery. Neurosurgery 89(3):E189, 2021. e-Pub 2021. PMID: 34131734.
38. Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, Wang J, Armstrong TS, Gilbert MR, Guha-Thakurta N, Wefel JS. A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro Oncol 23(8):1337-1347, 2021. e-Pub 2021. PMID: 33647972.
39. Wefel JS, Armstrong TS, Pugh SL, Gilbert MR, Wendland MM, Brachman DG, Roof KS, Brown PD, Crocker IR, Robins HI, Hunter G, Won M, Mehta MP. Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825). Neuro Oncol 23(7):1125-1138, 2021. e-Pub 2021. PMID: 33515019.
40. Quirarte JA, Kumar VA, Liu HL, Noll KR, Wefel JS, Lang FF. Language supplementary motor area syndrome correlated with dynamic changes in perioperative task-based functional MRI activations: case report. J Neurosurg 134(6):1-5, 2021. e-Pub 2020. PMID: 32502992.
41. Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA. CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. Neuro Oncol 23(3):457-467, 2021. e-Pub 2021. PMID: 32678879.
42. De Witt Hamer PC, De Witt Hamer PC, Klein M, Hervey-Jumper SL, Wefel JS, Berger MS. Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery. Neurosurgery 88(4):720-732, 2021. e-Pub 2021. PMID: 33517431.
43. Noll KR, Chen HS, Wefel JS, Kumar VA, Hou P, Ferguson SD, Rao G, Johnson JM, Schomer DF, Suki D, Prabhu SS, Liu HL. Alterations in functional connectomics associated with neurocognitive changes following glioma resection. Neurosurgery 88(3):544-551, 2021. e-Pub 2021. PMID: 33080024.
44. Mrugala MM, Ostrom QT, Pressley SM, Taylor JW, Thomas AA, Wefel JS, Coven SL, Acquaye AA, Haynes C, Agnihotri S, Lim M, Peters KB, Sulman EP, Salcido JT, Butowski NA, Hervey-Jumper S, Mansouri A, Oliver KR, Porter AB, Nassiri F, Schiff D, Dunbar EM, Hegi ME, Armstrong TS, van den Bent MJ, Chang SM, Zadeh G, Chheda MG. The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neurooncol Adv 3(1):vdab035, 2021. e-Pub 2021. PMID: 34007966.
45. Al Feghali KA, Randall JW, Liu DD, Wefel JS, Brown PD, Grosshans DR, McAvoy SA, Farhat MA, Li J, McGovern SL, McAleer MF, Ghia AJ, Paulino AC, Sulman EP, Penas-Prado M, Wang J, de Groot J, Heimberger AB, Armstrong TS, Gilbert MR, Mahajan A, Guha-Thakurta N, Chung C. Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv 3(1):vdab073, 2021. e-Pub 2021. PMID: 34337411.
46. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv 3(1):vdab079, 2021. e-Pub 2021. PMID: 34377987.
47. Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res 26(12):2789-2799, 2020. e-Pub 2020. PMID: 31969331.
48. Wefel JS. Improving access and standard of care for all. Neurooncol Pract 7(3):261-262, 2020. e-Pub 2020. PMID: 32537174.
49. Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA, Oncology FN. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 38(10):1019-1029, 2020. e-Pub 2020. PMID: 32058845.
50. Zeng Y, Dong J, Huang M, Zhang JE, Zhang X, Xie M, Wefel JS. Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. Int J Nurs Stud 104:103514, 2020. e-Pub 2020. PMID: 32004776.
51. Estevis E, Noll KR, Bradshaw ME, Wefel JS. Driver safety in patients with primary brain tumors. Neurooncol Pract 6(6):490-498, 2019. e-Pub 2019. PMID: 31832220.
52. Laack NN, Pugh SL, Brown PD, Fox S, Wefel JS, Meyers C, Choucair A, Khuntia D, Suh JH, Roberge D, Wendland MM, Bruner D. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neurooncol Pract 6(4):274-282, 2019. e-Pub 2019. PMID: 31386073.
53. Wefel JS. Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy. Neurooncol Pract 6(4):247-248, 2019. e-Pub 2019. PMID: 31386055.
54. Noll KR, Sullaway CM, Wefel JS. Depressive symptoms and executive function in relation to survival in patients with glioblastoma. J Neurooncol 142(1):183-191, 2019. e-Pub 2019. PMID: 30680509.
55. Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ, Movsas B. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery 84(1):66-76, 2019. e-Pub 2019. PMID: 29618054.
56. Harrison RA, Kesler SR, Johnson JM, Penas-Prado M, Sullaway CM, Wefel JS. Neurocognitive Dysfunction in Adult Cerebellar Medulloblastoma. Psychooncology 28(1):131-138, 2019. e-Pub 2019. PMID: 30315720.
57. Wefel JS. Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities. Neurooncol Pract 5(4):203, 2018. e-Pub 2018. PMID: 31385963.
58. Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. Neurooncol Pract 5(3):184-193, 2018. e-Pub 2018. PMID: 30094046.
59. Hardy SJ, Krull KR, Wefel JS, Janelsins M. Cognitive Changes in Cancer Survivors. Am Soc Clin Oncol Educ Book 38(38):795-806, 2018. e-Pub 2018. PMID: 30231372.
60. Noll KR, Bradshaw ME, Rexer J, Wefel JS. Neuropsychological practice in the oncology setting. Arch Clin Neuropsychol 33(3):344-353, 2018. e-Pub 2018. PMID: 29718081.
61. Armstrong TS, Vera E, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Bondy M, Scheurer ME. Association of genetic variants with fatigue in patients with malignant glioma. Neurooncol Pract 5(2):122-28, 2018. e-Pub 2018. PMID: 31386001.
62. Noll, KR, Bradshaw ME, Weinberg, Wefel JS. Neurocognitive functioning is associated with functional independence in patients with temporal lobe glioma. Neuro-Oncology Practice 5(3):184-193, 2018. e-Pub 2018.
63. Wefel JS. Patient-centered care in Neuro-Oncology. Neurooncol Pract 5(1):1, 2018. e-Pub 2018. PMID: 31385979.
64. Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?. J Clin Oncol 36(5):483-491, 2018. e-Pub 2018. PMID: 29272161.
65. Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY. Response Assessment in Neuro-Oncology (RANO): Clinical trial design for local therapies for brain metastases. Lancet Oncology, Lancet Oncol 19(1):e33-e42, 2018. e-Pub 2018.
66. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci 86:65-71, 2018. e-Pub 2018. PMID: 29180229.
67. Wefel JS, Parsons MW, Gondi V, Brown PD. Neurocognitive aspects of brain metastasis. Handb Clin Neurol 149:155-165, 2018. e-Pub 2018. PMID: 29307352.
68. Schagen SB, Wefel JS. Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All. J Natl Cancer Inst 109(10), 2017. e-Pub 2017. PMID: 28521366.
69. Hansen CC, Smith JB, Mohamed ASR, Mulcahy CF, Wefel JS, Hutcheson KA, Chrane K, Phan J, Frank SJ, Garden AS, Smith BD, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, Floris S, French C, Beadle BM, Morrison WH, Su SY, Lewis CM, Kupferman ME, Johnson JM, Skinner HD, Lai SY, Hanna EY, Rosenthal DI, Fuller CD, Gunn GB, Head MD, Working Group NCS. Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck 39(10):2048-2056, 2017. e-Pub 2017. PMID: 28763137.
70. El Salek KE, Hassan IS, Kotrotsou A, Abrol S, Faro SH, Mohamed FB, Zinn PO, Wei W, Li N, Kumar AJ, Weinberg JS, Wefel JS, Kesler SR, Liu HA, Hou P, Stafford RJ, Prabhu S, Sawaya R, Colen RR. Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study. Sci Rep 7(1):12054, 2017. e-Pub 2017. PMID: 28935966.
71. Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology 26(5):617-624, 2017. e-Pub 2017. PMID: 26677053.
72. Wefel JS, Noll KR, Rao G, Cahill DP. Reply to Freyschlag et al. Neuro Oncol 19(4):598-599, 2017. e-Pub 2017. PMID: 28339696.
73. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol 132(1):181-188, 2017. e-Pub 2017. PMID: 28116649.
74. Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol 131(3):565-574, 2017. e-Pub 2017. PMID: 27848136.
75. Wefel. Choosing clinical trial endpoints, aggregating data, and making clinical decisions. Neuro-Oncology Practice 4(4):199-200, 2017. e-Pub 2017.
76. Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 18(12):1656-1663, 2016. e-Pub 2016. PMID: 27576872.
77. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY) 8(12):3507-19, 2016. e-Pub 2016. PMID: 27992857.
78. Noll KR, Ziu M, Weinberg JS, Wefel JS. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. J Neurooncol 128(2):323-31, 2016. e-Pub 2016. PMID: 27022915.
79. Manchon JF, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci Rep 6:25705, 2016. e-Pub 2016. PMID: 27168474.
80. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34(9):945-52, 2016. e-Pub 2016. PMID: 26834058.
81. Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumours. Lancet Oncol 17(3):e97-108, 2016. e-Pub 2016. PMID: 26972863.
82. Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro Oncol 18 Suppl 2:ii13-ii20, 2016. e-Pub 2016. PMID: 26989128.
83. Noll KR, Weinberg JS, Ziu M, Wefel JS. Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Arch Clin Neuropsychol 31(1):37-46, 2016. e-Pub 2016. PMID: 26537777.
84. Noll KR, Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS. Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. Neurosurgery 77(5):777-85, 2015. e-Pub 2015. PMID: 26317672.
85. Noll KR, Wefel JS. Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function". Neuro Oncol 17(10):1421-2, 2015. e-Pub 2015. PMID: 26395063.
86. Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS. Genetic Modulation of Neurocognitive Function in Glioma Patients. Clin Cancer Res 21(14):3340-6, 2015. e-Pub 2015. PMID: 25904748.
87. Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol 17(4):580-7, 2015. e-Pub 2015. PMID: 25227126.
88. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 65(2):123-38, 2015. e-Pub 2015. PMID: 25483452.
89. Wefel JS. Neuro-Oncology Practice: Time Flies When You Are Having Fun!. Neurooncol Pract 1(4):143-144, 2014. e-Pub 2014. PMID: 26034625.
90. Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JE, Gritz ER. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology 23(6):626-33, 2014. e-Pub 2014. PMID: 24339329.
91. Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS. Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. EJC Suppl 12(1):29-40, 2014. e-Pub 2014. PMID: 26217164.
92. Wefel JS, Kornet RL, Schagen SB. Systemically Treated Breast Cancer Patients and Controls: an Evaluation of the Presence of Noncredible Performance. J Int Neuropsychol Soc 20(4):1-13, 2014. e-Pub 2014. PMID: 24607070.
93. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699-708, 2014. e-Pub 2014. PMID: 24552317.
94. Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute Cognitive Impairment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. Cancer 119(23):4188-95, 2013. e-Pub 2013. PMID: 24105672.
95. Kesler SR, Watson C, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, Wefel JS. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav 7(4):501-10, 2013. e-Pub 2013. PMID: 23536015.
96. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Mehta MP. Dose Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. J Clin Oncol 31(32):4085-91, 2013. e-Pub 2013. PMID: 24101040.
97. Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 31(32):4076-84, 2013. e-Pub 2013. PMID: 24101048.
98. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D, Oncology Group RT. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429-37, 2013. e-Pub 2013. PMID: 23956241.
99. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY, Neuro-Oncology group RAI. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 14(10):e396-406, 2013. e-Pub 2013. PMID: 23993384.
100. Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci U S A 110(28):11600-5, 2013. e-Pub 2013. PMID: 23798392.
101. Taychakhoonavudh S, Franzini L, Lal L, Chang E, Meyers CA, Wefel JS, Swint JM. Comparison of patient reported outcomes (pros) and clinician reported outcomes (cros) in patients with metastatic brain disease. Value Health 16(3):A145-6, 2013. e-Pub 2013. PMID: 23693422.
102. Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol 2(2):195-201, 2013. e-Pub 2013. PMID: 25057978.
103. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer. J Clin Oncol 31(7):895-902, 2013. e-Pub 2013. PMID: 23341526.
104. Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of Primary BrainTumor Patient and Caregiver Symptom Report. Cancer 118(20):5026-37, 2012. e-Pub 2012. PMID: 22415423.
105. Wefel JS, Schagen SB. Chemotherapy-Related Cognitive Dysfunction. Curr Neurol Neurosci Rep 12(3):267-75, 2012. e-Pub 2012. PMID: 22453825.
106. Johnson DR, Sawyer AM, Meyers CA, O'Neill BP, Wefel JS. Early Measures of Cognitive Function Predict Survival in Patients with Newly Diagnosed Glioblastoma. Neuro Oncol 14(6):808-16, 2012. e-Pub 2012. PMID: 22508762.
107. Schapiro R, Ferson D, Prabhu SS, Tummula S, Wefel J, Rao G. A Technique for Mapping Cortical Areas Associated with Speech Arrest. Stereotact Funct Neurosurg 90(2):118-123. e-Pub 2012. PMID: 22398728.
108. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 107(1):165-74, 2012. e-Pub 2012. PMID: 21964738.
109. Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS. Neurocognitive Function Before and After Surgery for Insular Gliomas. J Neurosurg 115(6):1115-25, 2011. e-Pub 2011. PMID: 21905800.
110. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703-8, 2011. e-Pub 2011. PMID: 21354373.
111. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583-93, 2011. e-Pub 2011. PMID: 21474379.
112. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(6):660-8, 2011. e-Pub 2011. PMID: 21558074.
113. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys 79(5):1487-95, 2011. e-Pub 2011. PMID: 20399573.
114. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 13(3):353-61, 2011. e-Pub 2011. PMID: 21310734.
115. Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER. Cognitive Impairment in Men with Testicular Cancer Prior to Adjuvant Therapy. Cancer 117(1):190-6, 2011. e-Pub 2011. PMID: 20737560.
116. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348-56, 2010. e-Pub 2010. PMID: 20564075.
117. Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery 146(6):1116-22, 2009. e-Pub 2009. PMID: 19879613.
118. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037-44, 2009. e-Pub 2009. PMID: 19801201.
119. Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and Affective Sequelae of Primary Hyperparathyroidism and Early Response to Parathyroidectomy. J Int Neuropsychol Soc 15(6):1002-11, 2009. e-Pub 2009. PMID: 19807940.
120. Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of Cognitive Decline in Hematopoietic Stem Cell Transplantation: A Within-subjects Design. Arch Clin Neuropsychol 24(7):689-98, 2009. e-Pub 2009. PMID: 19767298.
121. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208-15, 2008. e-Pub 2008. PMID: 18316473.
122. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19(4):623-629, 2008. e-Pub 2008. PMID: 17974553.
123. Mittendorf EA, Wefel JS, Meyers CA, Shapiro SE, Doherty DB, Lee JE, Evans DB, Perrier ND. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract 13(4):338-44, 2007. e-Pub 2007. PMID: 17669708.
124. Chang EL, Wefel JS, Maor MH, Hassenbusch SJ, rd, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60(2):277-83; discussion 283-4, 2007. e-Pub 2007. PMID: 17290178.
125. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 101(3):466-75, 2004. e-Pub 2004. PMID: 15274059.
126. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292-9, 2004. e-Pub 2004. PMID: 15160331.
127. Atchison TA, Sanders A, Struchen M, Roebuck T, Wefel JS, High W, Contant C. Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury. Clin Neuropsychol 18(2):249-265, 2004. e-Pub 2004. PMID: 15587672.
128. Wefel JS, Hoyt BD, Massman PJ. Cognitive Function in Depressed versus Non-Depressed AD Patients. The Clinical Neuropsychologist(13):249-257, 1999. e-Pub 1999.
129. Suhr J, Tranel D, Wefel J, Barrash J. Memory Performance after Head Injury: Contributions of Malingering, Litigation Status, Psychological Factors, and Medication Use. Journal of Clinical and Experimental Neuropsychology(19):500-514, 1997. e-Pub 1997.

Invited Articles

1. Lassman, A. B., Polley, M. C., Iwamoto, F. M., Sloan, A. E., Wang, T. J. C., Aldape, K. D., Wefel JS, Gondi, V., Gutierrez, A. N., Manasawala, M. H., Gilbert, M. R., Sulman, E. P., Wolchok, J. D., Green, R. M., Neil, E. C., Lukas, R. V., Goldlust, S. A., Snuderl, M., Galbraith, K., Dignam, J. J., Mehta, M. P.. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2500618, 2025. e-Pub 2025.
2. Gondi, V., Pugh, S. L., Mehta, M. P., Wefel JS, Tomé, W. A., Sun, A. Y., Grecula, J., Redmond, K. J., Fogh, S., Gaspar, L., Konski, A., Bovi, J., Robinson, C. G., Corn, B., Videtic, G. M., Lok, B. H., Yoon, H. A., Heinzerling, J. H., DeNittis, A. S., McGarry, R. C.. Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2500221, 2025. e-Pub 2025. PMID: 40789106.
3. Sheppard DP, Noll KR, Wefel JS, Bradshaw ME. Neuropsychological Evaluation for Oncology. Neurol Clin 42(4):875-887, 2024. e-Pub 2024. PMID: 39343481.
4. Wefel JS, Woods SP. Measuring everyday functioning in patients with brain tumor: The long rows yet to hoe. Neurooncol Pract 9(4):253-254, 2022. e-Pub 2022. PMID: 35859540.
5. Parsons MW, Peters KB, Floyd SR, Brown P, Wefel JS. Preservation of neurocognitive function in the treatment of brain metastases. Neurooncol Adv 3(5):v96-v107, 2021. e-Pub 2021. PMID: 34859237.
6. Noll KR, Walbert T, Wefel JS. Impaired neurocognitive function in glioma patients: from pathophysiology to novel intervention strategies. Curr Opin Neurol 33(6):716-722, 2020. e-Pub 2020. PMID: 33009006.
7. Noll KR, Bradshaw ME, Parsons MW, Dawson EL, Rexer J, Wefel JS. Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors. Curr Treat Options Neurol 21(7):33, 2019. e-Pub 2019. PMID: 31250277.
8. Wefel JS, Bradshaw ME. A Closer Look at the Effects of Cancer and Cancer Treatment on Cognitive Function. Coping with Cancer Magazine, 2019. e-Pub 2019.
9. Harrison RA, Wefel JS. Neurocognitive Function in Adult Cancer Patients. Neurol Clin 36(3):653-674, 2018. e-Pub 2018. PMID: 30072075.
10. Wefel JS, Bradshaw ME. Coping with the Cognitive Side Effects of Cancer. Coping Magazine, 2015. e-Pub 2015.
11. Day J, Yust-Katz S, Cachia D, Rooney A, Katz LH, Wefel J, Tremont I, Armstrong T. To assess the effective management of pharmacological and non-pharmacological interventions for reducing fatigue in patients with a primary brain tumour (PBT). Cochrane Gynaecological Cancer Group DOI:10.1002/14651858.CD011376, 2014. e-Pub 2014.
12. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13(12):1285-1295, 2008. e-Pub 2008. PMID: 19019972.
13. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 18(2):121-31, 2008. e-Pub 2008. PMID: 18415683.
14. Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther 13(4):362-9, 2006. e-Pub 2006. PMID: 16858172.
15. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 90(9):1691-6, 2004. e-Pub 2004. PMID: 15150608.

Review Articles

1. Mondia MWL, Avila EK, Wefel JS, Hehn RF, Bowers AR, Cox BS, Cox DJ, Schiff D. Brain tumors and fitness to drive: A review and multi-disciplinary approach. Neurooncol Pract 12(2):183-196, 2025. e-Pub 2025. PMID: 40110067.
2. Rock V, Ahluwalia MS, Anthony M, Arons D, Arzbaecher J, Dunbar E, Fraher C, Freund M, Gondi V, Khanuja S, Leach D, Loughan AR, Musella A, Oliver K, Paabo K, Puduvalli VK, Shaffer GD, Thomas AA, Wallgren K, Wefel JS, Yu JS, Zada G, Willmarth N, DeVitto R. Guiding principles for adult CNS tumor treatment programs. Neurooncol Adv 7(1):vdaf169, 2025. e-Pub 2025. PMID: 40980442.
3. Sheppard, D, Noll, KR, Wefel, JS, Bradshaw, ME. Neuropsychological Evaluation for Oncology. Neurologic Clinics 42(4):875-887, 2024. e-Pub 2024. PMID: 39343481.
4. Wilcox, JA, Chukwueke, U, Ahn, MJ, Aizer, A, Bale, T, Brandsma, D, Brastianos, PK, Chang, SM, Daras, M, Forsyth, P, Garzia, L, Glantz, MJ, Oliva, IC, Kumthekar, P, Le Rhun, E, Nagpal, S, O'Brien, BJ, Pentsova, E, Lee, EQ, Remsik, J, Ruda, R, Smalley, I, Taylor, MD, Weller, M, Wefel, JS, Yang, JT, Young, RJ, Wen, PY, Boire, A. Leptomeningeal metastases from solid tumors. Neuro-oncology 26(10):1781-1804, 2024. e-Pub 2024. PMID: 38902944.
5. Noll KR, Bradshaw M, Sheppard D, Wefel JS. Perioperative Neurocognitive Function in Glioma Surgery. Curr Oncol Rep 26(5):466-476, 2024. e-Pub 2024. PMID: 38573439.
6. Cowan BA, Olivier K, Tombal B, Wefel JS. Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes. Adv Ther 41(4):1770-1773, 2024. e-Pub 2024. PMID: 38378976.
7. Guran E, Hu J, Wefel JS, Chung C, Cata JP. Perioperative considerations in patients with chemotherapy-induced cognitive impairment: a narrative review. Br J Anaesth 129(6):909-922, 2022. e-Pub 2022. PMID: 36270848.
8. Beer TM, Shore N, Morgans A, Winters-Stone K, Wefel JS, George DJ. Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer. BJUI Compass 3(6):424-433, 2022. e-Pub 2022. PMID: 36267196.
9. Day J, Yust-Katz S, Cachia D, Wefel J, Tremont Lukats IW, Bulbeck H, Rooney AG. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev 9(9):CD011376, 2022. e-Pub 2022. PMID: 36094728.
10. Wefel JS, Ryan CJ, Van J, Jackson JC, Morgans AK. Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. CNS Drugs 36(5):419-449, 2022. e-Pub 2022. PMID: 35522374.
11. Schagen SB, Tsvetkov AS, Compter A, Wefel JS. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. Nat Rev Neurol 18(3):173-185, 2022. e-Pub 2022. PMID: 35140379.
12. Noll K, King AL, Dirven L, Armstrong TS, Taphoorn MJB, Wefel JS. Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. Hematol Oncol Clin North Am 36(1):269-282, 2022. e-Pub 2022. PMID: 34711455.
13. Lehrer EJ, Jones BM, Dickstein DR, Green S, Germano IM, Palmer JD, Laack N, Brown PD, Gondi V, Wefel JS, Sheehan JP, Trifiletti DM. The Cognitive Effects of Radiotherapy for Brain Metastases. Front Oncol 12:893264, 2022. e-Pub 2022. PMID: 35847842.
14. Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis 23(2):207-219, 2020. e-Pub 2020. PMID: 31844181.
15. van Lonkhuizen PJC, Klaver KM, Wefel JS, Sitskoorn MM, Schagen SB, Gehring K. Interventions for cognitive problems in adults with brain cancer: A narrative review. Eur J Cancer Care (Engl) 28(3):e13088, 2019. e-Pub 2019. PMID: 31090162.
16. Zeng Y, Zhang JE, Cheng ASK, Cheng H, Wefel JS. Meta-Analysis of the Efficacy of Virtual Reality-Based Interventions in Cancer-Related Symptom Management. Integr Cancer Ther 18:1534735419871108, 2019. e-Pub 2019. PMID: 31441352.
17. Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY, Neuro-Oncology group RAI. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol 19(1):e33-e42, 2018. e-Pub 2018. PMID: 29304360.
18. Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY. Addressing brain metastases from solid tumors within clinic trial designs for systemic agents: A guideline by the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group. Lancet Oncol 19(1):e20-e32, 2018. e-Pub 2018. PMID: 29304358.
19. Day J, Yust-Katz S, Cachia D, Wefel J, Katz LH, Tremont I, Bulbeck H, Armstrong T, Rooney AG. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev 4:CD011376. e-Pub 2016. PMID: 27074263.
20. Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of Cancer and Its Treatment on Cognitive Function: Advances in Research from the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage 50(6):830-41, 2015. e-Pub 2015. PMID: 26344551.
21. Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY, Neuro-Oncology group RAI. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 14(10):e407-16, 2013. e-Pub 2013. PMID: 23993385.

Professional Educational Materials

1. Wefel JS. Training Video and Website entitled, "Neurocognitive Test Battery". I authored and produced a training video that is used to teach standardized administration procedures for the core 'neurocognitive clinical trial battery' that is used in numerous cooperative group trials and sponsored trials for which I am the Neurocognitive Chair or consulting study neuropsychologist, 2007.
2. Wefel JS. Neurocognitive Test Administration and Training Manual. I authored a manual that is used in conjunction with the Training Video to teach standardized administration procedures for the core 'neurocognitive clinical trial battery' that is used in numerous cooperative group trials and sponsored trials for which I am the Neurocognitive Chair or consulting study neuropsychologist, 2007.

Other Articles

1. Gondi, V, Deshmukh, S, Brown, P, Wefel, JS, Armstrong, TS, Tomé, WA, Gilbert, MR, Konski, AA, Robinson, C, Bovi, J, Benzinger, TL, Roberge, D, Kundapur, V, Kaufman, I, Shah, SA, Usuki, K, Baschnagel, A, Mehta, MP, Kachnic, LA Erratum to. International Journal of Radiation Oncology Biology Physics 121(2):571-572, 2025. PMID: 39824575.
2. Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, Usuki KY, Baschnagel AM, Mehta MP, Kachnic LA Erratum to: Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117:571-580. Int J Radiat Oncol Biol Phys 121(2):571-572, 2025. PMID: 39824575.
3. Wefel J, Pugh S, Choucair A, Fisher B, Fox S, Meyers C, Ashby L, Mikkelsen T, Glass J, Yu M, Howard S, Movsas B, Mehta M NCOG-01. NEUROCOGNITIVE FUNCTION (NCF) AND QUALITY OF LIFE (QOL) RESULTS FROM A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH RISK LOW-GRADE GLIOMAS. Neuro Oncol 21(6):vi158-9, 2019.
4. Wefel JS, Pugh S, Choucair A, Fisher B, Fox S, Meyers C, Ashby L, Mikkelsen T, Glass J, Yu M, Howard S, Movsas B, Mehta M NCOG-01. NEUROCOGNITIVE FUNCTION (NCF) AND QUALITY OF LIFE (QOL) RESULTS FROM A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH RISK LOW-GRADE GLIOMAS 21(6):vi158–9, 2019.

Editorials

1. Neth, BJ, Wefel, JS, Nead, KT. Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations. Translational Andrology and Urology 14(4):864-867, 2025. PMID: 40376525.
2. Wefel JS, Meyers CA. Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst 97(11):788-9, 2005. PMID: 15928294.
3. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557-8, 2003. PMID: 12913103.

Abstracts

1. Omuro, A, Wefel JS. Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: NRG/ RTOG 1114. EANO European Association of Neuro-Oncology. e-Pub 2025.
2. Wefel JS, Sullaway C, Danielsen JT, Cobb C, Noll K, Bajaj S, Quarles CC, Mohamed RM, Giordano S, Kumar V, Hou P, Kundu S, Sulman E, Tsvetkov A, Hu J, Chung C, Cata J, Patil KR, Neth BJ. Predictors of Cognitive Changes in Older Women with Breast Cancer: Results from a Prospective Longitudinal Observational Trial. Presented at The 9th International Cognition and Cancer Task Force Conference, 2025. e-Pub 2025.
3. Wefel JS, Noll K, Weiss H. An Exploratory Factor Analysis of the Beck Depression Inventory – Second Edition and Associations of Symptom Clusters with Biopsychosocial Factors and Quality of Life in Newly Diagnosed Primary Brain Tumor Patients. Presented at The International Neuropsychological Society, 2025. e-Pub 2025.
4. Corn BW, Paulus R, Gondi V, Mehta MP, Fogh S, Wefel JS, Videtic GM, Sun A, Yoon H, Heinzerling JH, McGarry RC, Kundapur V, Devisetty K, Wu A, Kanner AA, Pugh SL, Movsas B, Kachnic LA. “Hope"Drives Quality of Life in Patients with Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003. Journal of Clinical Oncology 42(Suppl 16):12011-12011, 2024. e-Pub 2024.
5. Cramer C, Wefel JS. A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma Patients Receiving Brain Radiotherapy. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
6. Abraham C, Pugh SL, Brown PD, Gondi V, Bovi JA, Robinson CG, Wefel JS, Roberge D, Kundapur V, Devisetty K, Shah SA, Usuki KY, Baschnagel AM, Stea B, Yoon HA, Li J, Laack NN, Jindal S, Borges M, Kachnic LA. RADT-01. Baseline Hippocampal Volume As A Predictor Of Neurocognitive Changes After WBRT Or HA-WBRT: Secondary Analysis Of NRG Oncology CC001. Neuro-Oncology 25(Supplement_5):v48, 2023. e-Pub 2023.
7. Bradshaw ME, Wefel JS, Noll KR, Rao G, Ferguson SD, Tawbi H, Huse J, Johnson J, Court L, O’Brien B, Lang F, Ejezie L, Sullaway C, Thomas A, Suki D, Yeboa DN. NCOG-01. Baseline patient-reported outcomes in an ongoing phase-III trial of pre-operative SRS vs. post-operative SRS for brain metastases. Neuro-Oncology 25(Supplement_5):v213, 2023. e-Pub 2023.
8. Noll KR, Chen HS, Bradshaw M, Wefel JS, Sullaway C, Thomas A, Kumar VA, Prabhu S, Liu HL. QOL-01. Variability in anxiety and depression symptoms after eloquent glioma resection is associated with changes in functional connectomic properties. Neuro-Oncology 25(Supplement_5):v248, 2023. e-Pub 2023.
9. Noll KR, Chen H, Bradshaw ME, Wefel JS, Sullaway C, Thomas A, Kumar V, Prabhu SS, Liu HL. Variability In Anxiety And Depression Symptoms After Eloquent Glioma Resection Is Associated With Changes In Functional Connectomic Properties. Neuro-Oncology 25(Suppl 5):v248, 2023. e-Pub 2023.
10. Sheppard DP, Goldberg M, McGranahan T, Graber JJ, Venur V, Figuracion KCF, Song YB, Wefel JS, Noll KR, Ferreira M, Halasz LM, Taylor LP. INNV-30.Development And Implementation Of A Novel, Brief Neurocognitive Screening And Rehabilitation Service In A Clinical Neuro-Oncology Setting. Neuro-Oncology 25(Supplement_5):v163, 2023. e-Pub 2023.
11. Noll KR, Bradshaw M, Chen HS, Wefel JS, Sullaway C, Thomas A, Kumar VA, Prabhu S, Liu HL. QOL-04. Changes in functional connectivity after surgery are associated with decline in functional independence in patients with eloquent glioma. Neuro-Oncology 25(Supplement_5):v249, 2023. e-Pub 2023.
12. Bovi JA, Pugh SL, Brown PD, Gondi V, Robinson CG, Wefel JS, Sabsevitz D, Sprenger MT, Kundapur V, Roberge D, Devisetty K, Shah SA, Usuki KY, Stea B, Yoon HA, Donnelly ED, Laack NN, Baschnagel AM, Paulus R, Kachnic LA. BIOM-03. Lack Of Correlation Of MR-Determined White Matter Injury(WMI)With Neurocognitive Function (NCF)6 Months Following WBRT+/-Hippocampal Avoidance(HA)+Memantine:Secondary Analysis Of NRG Oncology NRGCC001. Neuro-Oncology 25(Supplement_5):v4, 2023. e-Pub 2023.
13. Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala M, Gilbert MR, Sulman EP, Wolchok JD, Greene RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Dignam JJ, Won M, Movsas B, Mehta MP. A NRG Oncology Study BN007: Randomized Phase II/III Trial Of Ipilimiumab (Ipi) Plus Nivolumab (Nivo) Vs. Temozolomide (TMZ) In MGMT-Unmethylated (uMGMT) Newly Diagnosed Glioblastoma (nGBM). Neuro-Oncology 25(Supplement_2):ii2, 2023. e-Pub 2023.
14. Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel J, Gondi V, Gutierrez AN, Manasawala M, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil E, Lukas RV, Goldlust SA, Snuderl M, Dignam JJ, Won M, Movsas B, Mehta M. PL02.3.A NRG Oncology Study BN007: Randomized phase II/III trial of ipilimiumab (Ipi) plus nivolumab (Nivo) vs. temozolomide (TMZ) in MGMT-unmethylated (uMGMT) newly diagnosed glioblastoma (nGBM). Neuro-Oncology 25(Supplement_2):ii2, 2023. e-Pub 2023.
15. Phillips S, Burton EM, Kreidieh FY, Glitza IC, McQuade JL, Amaria RN, Diab A, Patel SP, Wong MK, Li J, Chung C, Milton DR, Malke J, Simon J, Wefel JS, Davies MA, Tawbi HA. Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM) 41(16), 2023. e-Pub 2023.
16. Burton EM, Kreidieh FY, Glitza IC, McQuade JL, Amaria RN, Diab A, Patel SP, Wong MKK, Li J, Chung C, Milton DR, Malke J, Simon J, Wefel JS, Davies MA, Tawbi HA. Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM). 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
17. Wefel JS, Noll KR, Rao G, Ferguson S, Tawbi H, Huse J, Johnson J, Court L, O/Brien B, Lang F, Ejezie L, Sullaway C, Thomas A, Suki D, Yeboa DN. Neurocognitive function and neurocognitive concerns in a phase III trial of pre-operative SRS versus post-operative SRS for brain metastases, 2023. e-Pub 2023.
18. Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel J, Gondi V, Gutierrez AN, Manasawala M, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil E, Lukas RV, Goldlust SA, Snuderl M, Dignam JJ, Won M, Movsas B, Mehta M. CTIM-18. NRG Oncology Study BN007: Randomized phase II/III trial of dual immune checkpoint blockade (ipilimiumab + nivolumab) vs. temozolomide in MGMT-unmethylated newly diagnosed glioblastoma. Neuro-Oncology 25(Supplement_5):v65-v65, 2023. e-Pub 2023.
19. Gondi V, Pugh S, Mehta MP, Wefel JS, Tome WA, Sun AY, Videtic GNM, Lok B, Yoon HA, Heinzerling JH, DeNittis AS, McGarry RC, Devisetty K, Kundapur V, Wu A, Paulus R, Kachnic LA. Primary endpoint results of NRG CC003: Phase IIR/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 117(4):e3, 2023. e-Pub 2023.
20. Eschler B, Bradshaw M, Wefel JS, Rexer J, Sullaway C, Noll K. Understanding Object Dysnomia in Patients With Left Hemisphere Primary Brain Tumors. Presented at the Biennial Meeting of the International Cognition and Cancer Task Force, San Diego, CA, January 30-31. 2023, 2023. e-Pub 2023.
21. Catalino M, Noll K, Prabhu S, Wefel JS. Resting Motor Threshold is Associated with Neurocognitive Function and Supports Global Oscillatory State Alterations in Low Grade Glioma Patients. Presented at the Biennial Meeting of the International Cognition and Cancer Task Force, San Diego, CA, January 30-31. 2023, 2023. e-Pub 2023.
22. Wefel JS, Sulman E, Tortarolo C, Sullaway C, Giordano S, Kumar V, Hou P, Hu J, Chung C, Cata J, Tsvetkov A, Kundu S. Cognitive Outcomes in Women Treated for HER2-negative Breast Cancer. Presented at the Biennial Meeting of the International Cognition and Cancer Task Force, San Diego, CA, January 30-31. 2023, 2023. e-Pub 2023.
23. Sullaway CM, Li J, Sulman EP, Pezzi TA, Noll KR, Tortarolo C, Wefel JS. Neurocognitive decline in patients with 4-20 brain metastases treated with stereotactic radiosurgery. Presented at the Annual Mid-Year Meeting of the International Neuropsychological Society, Barcelona, Spain, July 6-8, 2022. e-Pub 2022.
24. Weinberg JS, McAleer MF, Johnson JM, Kudchadker R, Wefel JS, Yuan Y, Lin HY. A phase III multi-center randomized controlled trial of postsurgical stereotactic radiotherapy versus surgically targeted radiation therapy (STaRT) for the treatment of large (>2.5cm) newly diagnosed brain metastases: Trial in progress. JCO 39:TPS2067-TPS2067, 2021. e-Pub 2021.
25. Cramer CK, Page BR, Wefel JS, Dressler EV, Ip E, Rapp SR, Shaw EG, Weaver K, Lesser GJ, Chan MD. NCOG-24. Wake Forest NCORP Research Base feasibility study of ramipril for preventing cogntiive decline in glioblastoma patients receiving brain radiotherapy (WF-1801). Neuro Oncol 22(Suppl 2):ii134, 2020. e-Pub 2020.
26. Omuro AMP, DeAngelis LM, Karrison T, Bovi JA, Rosenblum M, Corn BW, Correa D, Wefel JS, Aneja S, Grommes C, Schaff L, Waggoner SE, Lallana EC, Werner-Wasik M, Iwamoto F, Robinson TJ, Donnelly E, Struve T, Won M, Mehta MP. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). 2020 ASCO Virtual Scientific Program, Oral Abstract Session, J Clin Oncol 38:2020 (suppl; abstr 2501), 2020. e-Pub 2020.
27. Beer TM, Shore ND, Morgans AK, Winters-Stone KM, Wefel JS, Ortiz JA, Reeves JA, George DJ. DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC), 2020 ASCO Virtual Scientific Program, J Clin Oncol 38: 2020 (suppl; abstr TPS5587), 2020. e-Pub 2020.
28. Li J, Wang Y, Tang C, Welsh JW, Guha-Thakurta N, Carter BW, Wefel JS, Ghia AJ, Yeboa D, McAleer MF, Chung C, Woodhouse KD, Elamin Y, Le Y, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach J, Altan M. Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery from brain metastases from non-small cell lung cancer: A phase I trial. 2020 ASCO Virtual Scientific Program, J Clin Oncol 38: 2020 (suppl; abstr 2531), 2020. e-Pub 2020.
29. Wefel JS, Won M, Lassman AB, Stern Y, Wang TJC, Aldape K, Armstrong TS, Vogelbaum MA, Sulman EP, Moazami G, Macsai MS, Gilbert MR, Bain E, Blot V, Gan HK, Preusser M, Ansell PJ, Samanta S, Kundu MG, Seidel C, de Vos F, Hsu S, Cardona A, Lombardi G, Bentsion D, Peterson R, Gedye C, Lebrun-Frenay C, Wick A, Pugh S, Curran WJ, Mehta MP. Neurocognitive function (NCF) outcomes of RTOG Foundation 3508: A Phase 3 trial of ABT-414 with concurrent chemoradiation and adjuvant temozolomide in patients with EGFR-amplified newly diagnosed glioblastoma. 25th Annual Scientific Meeting of the Society for Neuro-Oncology, Austin, TX, November 18-22, 2020. e-Pub 2020.
30. Wefel JS, DeMora L, Gond V, Tsien CI, Chenevert T, Gilbert MR, Omuro A, Cao Y, Srinivasan A, Rogers CL, Shi W Nedzi L, Chan MD, Suh JH, Battiste JD, Mishra M, Shivnani A, Movsas B, Mehta M. Neurocognitive function (NCF) of the Photon Cohort in NRG-BN001. 25th Annual Scientific Meeting of the Society for Neuro-Oncology, Austin, TX, November 18-22, 2020. e-Pub 2020.
31. Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson JK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbum MA. CODEL: Phase III study of RT alone, RT plus Temozolomide, or Temozolomide alone for newly-diagnosed 1P/19O codeleted anaplastic oligodendroglioma patients. Updated analysis from the initial study design. 25th Annual Scientific Meeting of the Society for Neuro-Oncology, Austin, TX, November 18-22, 2020. e-Pub 2020.
32. Estevis E, Bradshaw ME, Wefel JS, Kesler Rexer J, Harmon CE, Rhines S, Noll K. Driver safety in patients with primary brain tumor 6(6):490-498, 2019. e-Pub 2019. PMID: 31832220.
33. Al Feghali KS, Randall JW, Wefel JS, Guha-Thakurta N, Grosshans D, Dibaj S, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, deGroot J, Heimberger A, Armstrong T, Gilbert M, Mahajan A, Brown PD, Chung C. Prospective Phase II Randomized Trial Comparing Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival Between RANO vs. Clinical and Radiological Assessment. Neuro-Oncology 21(6):vi161-vi162, 2019. e-Pub 2019.
34. Majd N, Mastall M, Hess K, Fuller G, Alfaro-Munoz K, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandberg DI, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Weathers S, Harrison R, deGroot J, Penas-Prado M. Characterization of Adult Medulloblastoma: A Retrospective Review of 200 Patients at MD Anderson Cancer Center. Neuro-Oncology 21(6):vi231-vi232, 2019. e-Pub 2019.
35. Randall J, Al Feghali K, Wefel J, Grosshans D, Dibaji S, Milton D, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, deGroot J, Heimberger A, Armstrong T, Gilbert M, Mahajan A, Brown P, Chung C. Prospective phase II Randomized Trial Comparing Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Gender and Neutrophil-Lymphocyte Ratio (NLR) in GBM Outcomes. Neuro-Oncology 21(6):vi213, 2019. e-Pub 2019.
36. Pollack A, Karrison TG, Balogh AG, Low D, Bruner DW, Wefel JS, Gomella LG, Martin AG, Michalski JM, Angyalfi S, Lukka H, Faria SL, Rodrigues G, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sandler HM. MP72-01. Improvements in freedom from progression with short term androgen deprivation therapy and pelvic lymph node treatment added to prostate bed salvage radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial. The Journal of Urology 201:e1054-1055, 2019. e-Pub 2019.
37. Gondi V, Deshmukh S, Brown PD, Wefel JS, Tome WA, Armstrong T, Bruner D, Bovi JA, Robinson CG, Khuntia D, Grosshans DR, Konski AA, Roberge D, Kundapur V, Devisetty K, Shah SA, Usuki K, Anderson BM, Mehta MP, Kachnic LA. NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM). JCO 37:2009-2009, 2019. e-Pub 2019.
38. Gondi V, Deshmukh S, Brown PD, Wefel JS, Tome WA, Armstrong T, Bruner D, Bovi JA, Robinson CG, Khuntia D, Grosshans DR, Konski AA, Roberge D, Kundapur V, Devisetty K, Shah SA, Usuki K, Anderson BM, Mehta MP, Kachnic LA. NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer. JCO 37:TPS8578-TPS8578, 2019. e-Pub 2019.
39. Gondi V, Deshmukh S, Brown PD, Wefel JS, Tome WA, Bruner DW, Bovi JA, Robinson CG, Khuntia D, Grosshans DR, Konski AA, Roberge D, Kundapur V, Devisetty K, Shah SA, Usuki KY, Anderson BM, Mehta MP, Kachnic LA. NCOG-01. Preservation of neurocognitive function with conformal avoidance of the hippocampus during whole-brain radiotherapy (HA-WBRT) for brian metastases: Preliminary results of phase III trial NRG Oncology CC001. Neuro Oncol 20(Suppl 6):vi172, 2018. e-Pub 2018.
40. Sheppard DP, Noll K, Wefel JS. NCOG-05. Intra-individual neurocognitive variability in patients with cancer: a predictor and marker of neurotoxicity associated with chemotherapy. Neuro-Oncology 20(suppl_6):vi173, 2018. e-Pub 2018.
41. Mastall M, Majid N, Fuller G, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandberg D, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weather S, Harrison R, de Groot J, Penas-Prado M. Adult medulloblastoma: analysis of use of chemotherapy in clinical practice. Neuro Oncol 20(Suppl 3):iii325, 2018. e-Pub 2018.
42. Wefel JS, Deshmukh S, Brown PD, Grosshans DR, Sulman EP, Cerhan JH, Mehta MP, Khuntia D, Shi W, Mishra MV, Suh JH, Laack NN, Chen Y, Curtis A, Laba JM, Mowat RB, Thakrar A, Pugh SL, Brunner DW. Impact of Appolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology's RTOG 0614. Int J Radiat Oncol Biol Phys 119(3):846-857, 2018. e-Pub 2018. PMID: 38101486.
43. Mastall M, Majid N, Fuller G, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandberg D, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weather S, Harrison R, de Groot J, Penas-Prado M. Characterization of adult medulloblastoma patients at recurrence: retrospective review of the MD Anderson experience. Neurooncol Adv 5(1):vdad032, 2018. e-Pub 2018. PMID: 37114244.
44. Pollack A, Karrison TG, Balogh AG, Low D, Bruner DW, Wefel JS, Gomella LG, Vigneault E, Michalski JM, Angyalfi S, Lukka H, Faria SL, Rodrigues G, Beauchemin MC, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sandler HM. Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial. International Journal of Radiation Oncology, Biology, Physics 102(5):1605, 2018. e-Pub 2018.
45. Schvartsman G, Glitza IC, Milton D, Amaria RN, Hwu P, Hwu W, Diab A, Wong MK, Patel SP, Wefel JS, Burton EM, Brown C, Woodman SE, Beosch IM Chung C, Davies MA, Tawbi HA. A phase II study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in patients with untreated melanoma brain metastases (BEAT-MBM):TPS9598-TPS9598, 2018. e-Pub 2018. PMID: 36.
46. Wefel JS, Tortarolo C, Giordano S, Rao V, Sulman E, Hou P, Kumar A, Kumar V, Kesler S. Subcomponent processes underlying learning and memory decline associated with cancer and cancer therapy in women with breast cancer, 2018. e-Pub 2018.
47. Salek KE, Hassan IS, Faro SH, Mohamed FB, Zinn PO, Wei A, Li N, Kumar AJ, Weinberg JS, Wefel JS, Abrol S, Kesler SR, Liu HA, Hou P, Stafford RJ, Prabhu S, Sawaya R, Colen RR. Silence Sentence Completion Paradigm Shows Superiority in Localization of Wernicke's Area and Changes in Functional Activation in the Distinct Language Paradigms Correlate with Key Genomic Markers: A Prospective Study 7(1):12054, 2017. e-Pub 2017. PMID: 28935966.
48. Harrison RA, Sullaway CM, Kesler SR, Johnson JM, Wefel JS. Neurocognitive Profiles of Adults with Cerebellar Medulloblastoma. Neurology 88(Suppl 16), 2017. e-Pub 2017.
49. Wefel JS, Patwardhan SY, Bradshaw ME, Massman PJ. Validity and diagnostic accuracy of the clinical trial battery in patients with primary brain tumor, 2017. e-Pub 2017.
50. Verhaak AS, Arbona CA, Day SX, Wefel JS. Prediction of subjective memory ability and patient self-report accuracy before resection of high grade glioma, 2017. e-Pub 2017.
51. Moruno Manchon JF, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci Rep 6:25705, 2016. e-Pub 2016. PMID: 27168474.
52. Jaeckle K, Vogelbaum M, Ballman KV, Anderson SK, Giannini C, Aldape K, Cerhan J, Wefel JS, Nordstrom D, Jenkins R, Klein M, Raizer J, Van Den Bent M, Wick W, Flynn P, Dhermain F, Cairncross, Galanis E, Brown P. CODEL (Alliance –N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2); Phase III Randomized Study of RT vs RT+TMZ vs TMZ for Newly Diagnosed 1p/19q-Codeleted Anaplastic Oligodentroglial Tumors, Analysis of Patients Treated on the Original Protocol Design. Neurology 86(Suppl 16):PL02.005, 2016. e-Pub 2016.
53. Kesler SR, Tortarolo C, Giordano SH, Hou P, Kumar AJ, Jones JR, Jackson E, Wefel JS. Longitudinal Changes in Brain Network Local Efficiency and Verbal Memory Performance Following Breast Cancer Chemotherapy, 2016. e-Pub 2016.
54. Hansen CC, Chrane K, Gunn GB, Mohamed ASR, Rosenthal DI, Wefel JS, Phan J, Frank SJ, Garden AS, Smith B, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, Floris S, French C, Beadle BM, Morrison WH, Su SY, Hanna EY, Lewis CM, Skinner HD, Lai S, Fuller CD. Cognitive function and patient-reported memory problem following radiation therapy for cancers at the skull base: A survivorship study using the Telephone Interview for Cognitive Status and the MDASI-HN. IJROBP 94(4):967, 2016. e-Pub 2016.
55. Vera E, Scheurer ME, Zhou R, Acquaye A, Berger A, Breton G, Mahajan A, Wefel J, Gilbert MR, Amstrong TS. Investigation of risk factors associated with fatigue in glioma patients. JCO 34:2018-2018, 2016. e-Pub 2016.
56. Demeriva P, Noll KR, Sellin J, Prabhu S, Wefel J. Neurocognitive changes associated with frontal lobectomy for right and left frontal lobe glioma. Neuro Oncol 17(Suppl 5):v148-9, 2015. e-Pub 2015.
57. Wefel JS, Bradshaw ME, Sullaway CM, Gilbert MR, Armstrong TS. NCO-17: A brain-plasticity based computerized intervention to treat attention and memory problems in adult brain tumor (BT) survivors. Neuro Oncol 17(Suppl 5):v149-50, 2015. e-Pub 2015.
58. Verhaak AS, Arbona CA, Day SX, Wefel JS. Prediction of subjective memory ability before resection of high grade glioma. Neuro Oncol 17(Suppl 5):v149, 2015. e-Pub 2015.
59. Kesler S, Noll K, Cahill D, Rao G, Wefel J. NIMG-42: Lower brain network efficiency in IDH1 wild type (IDH1-WT) malignant astrocytoma compared to IDH1 mutant (IDH1-M). Neuro Oncol 17(Suppl 5):v163, 2015. e-Pub 2015.
60. Wefel JS, Sulman EP, Zhou R, Liu Y, Scheurer ME, Bondy ML. Genetic modulation of neurocognitive decline in glioma patients. Clin Cancer Res 21(14):3340-6, 2015. e-Pub 2015. PMID: 25904748.
61. Noll, KR, Narang S, Martinez J, Rao G, Wefel J, Rao A. Relationships between tumor compartment volumes and neurocognitive functioning in patients with temporal lobe glioma. Neuro Oncol 17(Suppl 5):580-7, 2015. e-Pub 2015. PMID: 25227126.
62. Mehta MP, Gondi V, Pugh SL, Tome WA, Wefel JS, Fogh SE, Movsas B, Konski AA, Lassman AB, Robinson CF, Bovi JA, Benzinger TLS, Redmond KJ, Sun A, Bruner DW. NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer, 2015. e-Pub 2015.
63. Noll KR, Narang S, Martinez J, Rao G, Wefel J, Rao A. Tumor volumetric and textural feature predictors of neurocognitive impairment in patients with temporal lobe glioma. Neuro Oncol 17(Suppl 5):v148, 2015. e-Pub 2015.
64. Noll KR, Wang X, Shi Q, Wefel J. Neurocognitive functioning, gender, and inflammatory markers in patients with colorectal cancer prior to chemotherapy. Journal of the International Neuropsychological Society 21(Suppl 1):292, 2015. e-Pub 2015.
65. Noll K, Garbarino A, Turner C, Verhaak AMS, Wefel J. Depression and executive function in relation to survival in patients with glioblastoma. Neuro Oncol 16(Suppl 5):v136, 2014. e-Pub 2014.
66. Wefel J, Noll K, Rao G, Cahill D. Relationships between neurocognitive functioning and IDH1 genetic mutation status in malignant astrocytoma. Neuro Oncol 16(Suppl 4):580-7, 2014. e-Pub 2014. PMID: 25227126.
67. Kesler, SR, Wefel. Default mode network connectivity as a potential biomarker of chemotherapy-related cognitive deficit 35(Suppl 2):S11-9, 2014. e-Pub 2014. PMID: 24913897.
68. Turner C, Noll K, Strange C, Bradshaw M, Wefel JS. Quality of life, mood, and neurocognitive functioning in patients with temporal lobe glioma. Neuro-Oncology 15(Suppl 3):iii96, 2014. e-Pub 2014.
69. Wefel JS, Noll K, Rao G, Cahill D. NC-15: Relationships between neurocognitive functioning and IDH1 genetic mutation status in malignant astrocytoma. Neuro Oncol 16(Suppl 5):v137, 2014. e-Pub 2014.
70. Noll K, Turner C, Garbarino A, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe. Poster session presented at the Cancer Survivorship Research Symposium, The University of Texas M. D. Anderson Cancer Center, Houston, 2014. e-Pub 2014.
71. Noll K, Weinberg J, Ziu M, Turner C, Strange C, Wefel JS. Verbal learning and encoding strategies in patients with glioma of the right and left temporal lobes. Neuro-Oncology 15(Suppl 3):iii92-iii97, 2013. e-Pub 2013.
72. Taychakhoonavudh S, Franzini L, Lal L, Chang E, Meyers CA, Wefel JS, Swint JM. Comparision of Patients Reported Outcomes (PROS) and Clinician Reported Outcomes (CROS) in Patients with Metastastic Brain Disease. Value in Health 16(3):A145-A146, 2013. e-Pub 2013.
73. Bradshaw ME, Noll K, Ziu M, Weinberg J, Strange C, Turner C, Wefel JS. Neurocognitive functioning and functional status in patients with glioma of the temporal lobes. Neuro-Oncology 15(Suppl 2):iii92, 2013. e-Pub 2013.
74. Ziu M, Noll K, Weinberg, J, Benveniste R, Turner C, Strange C, Suki D, Wefel JS. Neurocognitive functioning in patients with glioma of the right and left temporal lobes. Neuro-Oncology 15(Suppl 3):iii97, 2013. e-Pub 2013.
75. Resendiz CV, Armstrong TS, Acquaye A, Vera-Bolanos E, Gilbert M, Wefel JS. When do patients/caregive report of cognitive symptoms predict neurocognitive dysfunction?, 2013. e-Pub 2013.
76. Turner C, Strange C, Bradshaw M, Noll K, Wefel JS. Quality of life, mood, and neurocognitive functioning in patients with temporal lobe glioma. Neuro-Oncology 15(Suppl 3):iii96, 2013. e-Pub 2013.
77. Gning I, Armstrong TS, Wefel JS, Acquaye AA, Vera-Bolanos E, Tito R, Mendoza TR, Gilbert MR, Cleeland CS. Assessing The Validity of the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Using Caregiver Proxy Report, 2012. e-Pub 2012.
78. Gehring K, Sawyer AM, Etzel CJ, Lang FF, Wefel JS. NC-11. Prediction of Memory Outcomes after Resection of High Grade Glioma. Neuro-Oncology 13(Suppl 3):75-75, 2011. e-Pub 2011.
79. Wefel JS, Patwardhan SY, Strange C. Concurrent and criterion validity related evidence for the neurocognitive function clinical trial battery in brain tumor patients. Neuro-Oncoloy 12(4):iv58-iv61, 2010. e-Pub 2010.
80. Patwardhan S, Fitzgerald K, Meyers C, Wefel J. Comparison of Trail Making Tests A and B Standard Scores Based on Heaton and Tombaugh Systems, 2010. e-Pub 2010.
81. Patwardhan SY, Teo I, Wefel JS, Levin VA. Quality of life associated with tumor laterality among hypothyroid patients with primary brain tumors receiving thyroid hormone supplements, 2010. e-Pub 2010.
82. Patwardhan SY, Myszka KA, Collins R, Etzel CJ, Meyers CA, Wefel JS. Assessment of the Efficacy of Immediate Release Methylphenidate, Sustained Release Methylphenidate, and Modafinil for Patients with Primary Brain Tumor, 2010. e-Pub 2010.
83. Wefel JS, Patwardhan S, Levin VA. Neurocognitive outcomes associated with combined levothyroxine/liothyronine supplementation in hypothyroid patients with primary brain tumors 11(5):642, 2009. e-Pub 2009.
84. Armstrong TS, Wefel JS, Gning I, Vera-Bolanos E, Acquaye A, Mendoza T, Gilbert MR, Kayl AE, Cleeland C. Congruence of Caregiver and Patient Symptom Report and Association with Patient Neurocognitive Status. Presented as an Oral Presentation at the 2009 Joint Meeting of the Society for Neuro-Oncology and AANS/CNS Section on Tumors. Neuro-Oncology 11(5):562, 2009. e-Pub 2009.
85. Vredenburgh JJ, Wefel J, Cloughesy T, Zazzali J, Samant M, Zheng M, Fang L, Das A, BRAIN Investigators FHFT. 8707 Clinical Assessment of Corticosteroid Use and Neurocognitive Function in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study. European Journal of Cancer Supplements 7(2):495-496, 2009. e-Pub 2009.
86. Wefel J, Cloughesy T, Zazzali J, BRAIN Investigators FHFT. Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study. JCO 27 27(Suppl 15):2056-2056, 2009. e-Pub 2009.
87. Witgert M, Chang E, Wefel J. Acute effects of stereotactic radiosurgery +/- whole brain radiation therapy on fatigue in patients with brain metastases, 2008. e-Pub 2008.
88. Veramonti T, Wefel J. Neurocognitive Interventions for Brain Tumor Patients Case Report, 2008. e-Pub 2008.
89. Witgert M, Lang F, Suki D, Chang E, Meyers C, Wefel J. Baseline cognitive impairment in patients with single brain metastasis, 2007. e-Pub 2007.
90. Benveniste RJ, Wefel JS, Meyers CA, Hlatky R, Weinberg JS. Neurocognitive Deficits Following Resection of Right Temporal Lobe Gliomas, 2007. e-Pub 2007.
91. Kim SS, McCutheon IE, Sawaya R, Weinberg JS, Lang FF, Heimberger AB, DeMonte F, Hassenbusch SJ, Rhines L, Ferson DZ, Wefel JS, Suki D, Prabhu SS. Awake Craniotomy for Brain Tumors Near Eloquent Cortex: Correlation of Intraoperative Cortical Mapping with Neurological Outcomes in 300 Consecutive Patients, 2007. e-Pub 2007. PMID: 19404147.
92. Veratmonti TL, Pappas C, Meyers CA, Wefel JS. Factor Analysis of the Functional Assessment of Cancer Therapy - Brain module in a Primary Brain Tumor Population at Time of Diagnosis, 2007. e-Pub 2007.
93. Wefel JS, Veramonti TL, Bruera E, Davenport SD, Meyers CA. Cognitive Outcomes of a Pilot Trial Examining Donepezil for the Treatment of Opioid-induced Sedation in Cancer Patients, 2007. e-Pub 2007.
94. Ferson D, Chi L, Jackson E, Meyers C, Mahankali S, Wefel J, Sawaya R. Correlation of Preoperative fMRI with Intraoperative Speech Mapping in a Trilingual Patient. Journal of Neurosurgical Anesthesiology 18(4):275-276, 2006. e-Pub 2006.
95. Wefel JS, Meyers CA. “Chemobrain?” Pre-chemotherapy cognitive impairment in women with breast cancer 101(3):466-475, 2004. e-Pub 2004.
96. Wefel JS, Meyers CA. Tamoxifen associated neurotoxicity in women with breast cancer, 2004. e-Pub 2004.
97. Chang E, Wefel JS, Meyers CA, Mahajan A, Mathews LA, Smythe L, Allen PK, Hassenbusch SJ, Maor MH. Prospective Neurocognitive Evaluation of Patients with 1 to 3 Newly Diagnosed Brain Metastases Treated with Stereotactic Radiosurgery Alone. International Journal of Radiation Oncology, Biology, Physics 60(1):S164-165, 2004. e-Pub 2004.
98. Wefel JS, Lang F, Nader R, Meyers CA. Neurocognitive sequelae of surgical resection for previously untreated intrinsic insular region tumor. Neuro-Oncology 5:335, 2003. e-Pub 2003.
99. Sander AM, Wefel JS, High WM, Contant C. Impact of family functioning on community integration after TBI. Journal of the International Neuropsychological Society 7(2):178, 2001. e-Pub 2001.
100. High WM, Wefel JS, Sander AM, Boake C, Robinson K, Contant C, Hannay HJ. Comparison of the Glasgow Outcome Scale and Disability Rating Scale as a measure of outcome after TBI. Journal of the International Neuropsychological Society 7:175, 2001. e-Pub 2001.
101. Wefel J, Meyers CA. Qualitative performance on the Benton Visual Retention Test in patients with primary brain tumors. J International Neuropsychological Society 7:253, 2001. e-Pub 2001.
102. Cole L, Glosser G, Hiscock M, Wefel JS. Implications for mesial temporal lobe involvement in memory retrieval: evidence from temporal lobectomy, 2000. e-Pub 2000.
103. Sander AM, High WM, Wefel JS, Contant C. Dimensions of family response to TBI: Relationship to patient outcome. Archives of Physical Medicine and Rehabilitation 81:1621, 2000. e-Pub 2000.
104. Wefel JS, Friedman MA, Meyers CA. Benton Visual Retention Test performance in patients with primary brain tumors. Journal of the International Neuropsychological Society 5:141, 1999. e-Pub 1999.
105. Mochache M, Bradshaw ME, Prabhu SS, Wefel JS, Noll KR. Prediction of Baseline and Postoperative Change in Verbal Episodic Memory from Learning Characteristics in Patients with Glioma Undergoing Awake Craniotomy. Accepted for presentation at the 54th Annual North American Meeting of the International Neuropsychological Society.
106. Wefel JS, Noll KR, Rao G, Ferguson S, Tawbi H, Huse J, Johnson J, Court L, O/Brien B, Lang F, Ejezie L, Sullaway C, Thomas A, Suki D, Yeboa DN. Neurocognitive function and neurocognitive concerns in a phase III trial of pre-operative SRS versus post-operative SRS for brain metastases. Presented at the 2023 SNO/ASCO Cancer Conference.
107. Gondi V, Pugh S, Mehta MP, Wefel JS, Tome WA, Sun A, Videtic GM, Lok BH, Yoon HA, Heinzerling JH, DeNittis AS, McGarry RC, Devisetty K, Kundapur V, Wu AJ, Paulus R, Kachnic LA. Primary endpoint results of NRG CC003: Phase IIR/III trial of prophylactic cranial irradiation (PCI) with or without hippocampal avoidance (HA) for small cell lung cancer (SCLC). 2023 ASTRO Annual Meeting.
108. Bajaj S, Quarles CC, Giordano S, Kumar V, Hou P, Kundu S, Sulman E, Tsvetkov A, Hu J, Chung C, Cata J, Noll K, Sullaway C, Patil K, Wefel JS. The Neurobiological Footprint of Breast Cancer Chemotherapy: Gray Matter Changes and Signs of Accelerated Brain Aging. Oral presentation, Meeting of the International Neuropsychological Society.
109. Danielsen JTT, Zachariae R, Schmidt H, Kallehauge JF, Thomasdsen JK, Wefel JS, Wu LM, Amidi A. Cognition and cerebral gray matter in patients with melanoma undergoing adjuvant immunotherapy. Poster presentation, Meeting of the International Cognition and Cancer Task Force.
110. Neth B, Nguyen A, Raghunathan A, Ghaffar U, Alden E, Botha H, Ramanan V, Petersen R, Jack C, Knopman D, Ruddy K, Childs D, Karnes J, Wefel JS, Vemuri P, Graff-Radford J. Assessment of Alzheimer's disease neuropathologic change in cognitively impaired prostate cancer survivors. Oral presentation, Meeting of the International Cognition and Cancer Task Force.
111. Tasnim I, Asman P, Swamy C, Connelly K, Muir M, Hall M, Wefel JS, Bajaj S, Pellizzer G, Ince N, Prabhu S, Noll K. Relationships between intraoperative gamma band electrocorticograms, direct electrical stimulation, and cognitive-linguistic outcomes in patients with language-eloquent brain tumors. Poster presentation, Meeting of the International Cognition and Cancer Task Force.
112. Diaz Escarcega R, Wefel JS, Morales R, Tsvetkov A. Methotrexate upregulates indoleamine 2, 3-dioxygenase 1 in neurons and exacerbates disease phenotypes in a model of Alzheimer's disease. Poster presentation, Meeting of the International Cognition and Cancer Task Force.
113. Noll K, Muir M, Prinsloo S, Michener H, Asman P, Kumar V, Bradshaw M, Wefel JS, Liu HL, Taylor B, Prabhu S. Influence of tractography seeding and thresholding upon relationships between surgical trauma to white matter tracts and postoperative neurocognitive outcome following resection of language-eloquent glioma. Oral presentation, Meeting of the International Cognition and Cancer Task Force.
114. Bajaj S, Quarles CC, Sullaway C, Danielsen JT, Mohamed RM, Giordano S, Kumar V, Hou Ping, Kundu S, Sulman E, Tsvetkov A, Hu J, Chung C, Cata J, Noll K, Cobb C, Patil KR, Neth BJ, Wefel JS. Accelerated Brain Aging in Breast Cancer Survivors: Grey Matter Alterations Post- Chemotherapy and Their Association with Cognitive Function. Poster presentation, Meeting of the International Cognition and Cancer Task Force.
115. Mochache M, Bradshaw ME, Prabhu SS, Wefel JS, Noll KR. Relationships between single trial learning and baseline and preoperative change in verbal episodic memory in eloquent glioma patients. Presented at the Houston Neuropsychological Society Annual Symposium.
116. Bradshaw ME, Noll KR, Goethe E, Srinivasan S, Prabhu SS, Weinberg JS, McCutcheon IE, Lang FF, Wefel JS, Ferguson SD. Neurocognitive outcomes after resection of left inferior parietal lobule gliomas. Accepted for presentation at the 30th Annual Meeting of the Society for Neuro-oncology.
117. Wefel JS, Noll KR, Sullaway CM, Bradshaw ME. Breast cancer survivors exhibit elevated rates of inattention and poor vigilance on the Conners’ Continuous Performance Test-3. Accepted for presentation at the 54th Annual North American Meeting of the International Neuropsychological Society.

Book Chapters

1. Al Feghali KA, Bradshaw ME, Chung C, Wefel JS. Neurocognitive Effects on Brain Metastases and Their Treatment. In: Central Nervous System Metastases: Diagnosis and Treatment. Springer Nature, 2020.
2. Gehring K, Kiaver K, Edwards ML, Kesler S, Wefel JS. Cognitive Rehabilitation in Patients with Non-Central Nervous System Cancer and Brain Tumors. In: Cognitive Rehabilitation and Neuroimaging: Examining the Evidence from Brain to Behavior. Springer, 2020.
3. Sabsevitz DS, Elverman KH, Wefel J, Noll K. Neuropsychologist's Role in the Management of Brain Tumor Patients. In: Brain Mapping: Indications and Techniques. Thieme, 2020.
4. Noll K, Sabsevitz D, Prabhu S, Wefel J. Neuropsychology in the Neurosurgical Management of Primary Brain Tumors. In: Neurosurgical Neuropsychology: The application of neuropsychology to the practice of neurosurgery. Elsevier, 2019.
5. Bradshaw ME, Wefel JS. Neuropsychological Assessment of Older Adults with a History of Cancer. In: Handbook on the Neuropsychology of Aging and Dementia. 2nd. Springer, 2018.
6. Kesler SR, Wefel JS. Targeted Treatment for Cognitive Impairment Associated with Cancer and Cancer Treatment. In: Working to Better the Brain: Clinical Scientific Research on Cognitive Enhancement. Oxford University Press, 2018.
7. Brown PD, Schagen SB, Wefel JS. Cognitive Function in Cancer Patients. In: DeVita, Hellman, and Rosenberg's Cancer Principles and Practices of Oncology. 10th. Lippincott, Williams & Wilkins, 2015.
8. Witgert ME, Wefel JS. The Neuropsychology of Oncology. In: Clinical Neuropsychology: A Pocket Handbook for Assessment. 3rd. APA, 2014.
9. Cohen MZ, Shonka NA, Armstrong TS, Wefel JS. Cognitive Dysfunction. In: Cancer Symptom Management. 4th. Jones and Bartlett Learning, 2014.
10. Noll KR, Wefel JS. Quality of Life and Neurocognitive Function. In: Neuro-Oncology: The Essentials. 3rd. Thieme Medical Publishers, Inc, 2014.
11. Witgert ME, Wefel JS. Neuropsychological Assessment of Older Adults with a History of Cancer. In: Handbook on the Neuropsychology of Aging and Dementia. Springer, 443-454, 2013.
12. Witgert ME, Wefel JS. Neurobehavioral Side Effects of Cancer and Cancer Therapy. In: MD Anderson Manual of Psychosocial Oncology. McGraw-Hill, 179-188, 2011.
13. Meyers CA, Wefel JS. Cognitive Dysfunction. In: Cancer Symptom Science. Cambridge University Press, 51-59, 2011.
14. Brown PD, Laack NN, Wefel JS. Neurocognitive Effects. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practices of Oncology. 9th. Lippincott, Williams & Wilkins, 2011.
15. Wefel JS, Armstrong TA, Kohli S. Neuropsychological Function, Symptom Measurement and Quality of Life in Brain Tumor Patients. In: Primary CNS Tumors: Pathogenesis and Therapy. Humana Press/Springer, 2010.
16. Kayl AE, Collins RL, Wefel JS. Neuropsychological Assessment of Adults with Cancer. In: Cognition and Cancer. Cambridge University Press, 2009.
17. Smith JA, Wefel JS. Neurocognitive Testing in Clinical Trials. In: Cognition and Cancer. Cambridge University Press, 2009.
18. Wefel JS, Collins RL, Kayl AE. Chemotherapy and Biological Response Modifier-Related Cognitive Dysfunction. In: Cognition and Cancer. Cambridge University Press, 2009.
19. Meyers CA, Wefel JS. Quality of Life. In: Neuro-Oncology: The Essentials, 2nd Edition. M Bernstein, MS Berger, 2008.
20. Burton AW, Veramonti TL, Phan PC, Wefel JS. Symptom Management for Patients with Brain Tumors: Improving Quality of Life. In: MD Anderson Cancer Center Series: Tumors of the Brain and Spine. Springer, 2007.
21. Wefel JS Janus T. Neurology and Neuropsychology in Oncology. In: Principles and Practice of Behavioral Neurology and Neuropsychology. P.M. Gordon Associates, Inc, 2003.
22. Bradshaw ME, Wefel JS. Cancer and Cognition. In: Neuropsychology of Alzheimer's Disease and Other Dementias. 2nd. Oxford University Press.
23. Al Feghali KA, Chung C, Wefel JS, Bradshaw. Neurocognitive Toxicity from Radation Therapy for Brain Metastases. In: Central Nervous System Metastases. Springer Nature.

Books (edited and written)

1. . Cancer, Cancer Therapy and Nervous System Toxicity. Springer Publishing Company.

Letters to the Editor

1. Wefel JS, Noll KR, Rao G, Cahill DP. Reply to Freyschiag et al. Neuro Oncol, 2017.
2. Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M. C. Chamberlain. J Clin Oncol 32: 1634-5, 2014.
3. Welsh JW, McGovern SL, Wefel JS, Komaki R, Brown PD, Soh HE. Reply to V. R. Bhatt et al and M. C. Chamberlain. Journal of Clinical Oncology 31: 3165-6, 2013.
4. Wefel JS, Meyers CA. Reply to Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 117: 1103-4, 2011.
5. Wefel JS, Meyers CA. Response to Heflin et al. Journal of the National Cancer Institute 97: 1551-1552, 2005.
6. Wefel JS, Meyers CA, Davis RN. Reply to Maruff et al. Cancer 101: 2144-2145, 2004.